Shantha Kumara Hmc, Hedjar Yanni, Mitra Neil, Miyagaki Hiromichi, Yan Xiaohong, Cekic Vesna, Whelan Richard L
Northwell, New Hyde Park, NY 10042-1069, USA.
Division of Colon and Rectal Surgery, Department of Surgery, Lenox Hill Hospital, Northwell Health, New York, NY, USA.
J Gastrointest Oncol. 2024 Oct 31;15(5):2157-2165. doi: 10.21037/jgo-24-114. Epub 2024 Oct 12.
Progranulin (PGRN), also identified as Precursor cell-derived growth factor (PCDGF), is a glycoprotein that is expressed and released ubiquitously. PGRN is plays a crucial role in regulating cell proliferation, differentiation, and pathological pathways. PGRN overexpression has been noted in many cancers and plays an important role in wound healing. Surgery's impact on PGRN levels is unknown. The aim of this study was to assess the levels of plasma PGRN before during the first month after minimally invasive colorectal resection (MICR) for colorectal cancer (CRC) resection.
CRC patients who were enrolled in a data/plasma bank approved by an Institutional Review Board and underwent MICR for whom adequate plasma samples were available were studied. Blood samples were obtained before surgery and at different time intervals after the operation and late samples were grouped into 7-day blocks and considered as single time points. PGRN levels (pg/mL) were determined in duplicate via ELISA and reported as median and 95% confidence interval (95% CI) values. The paired -test was used for statistical analysis.
Preoperative and 1 or more late postoperative plasma sample were available for 93 MICR CRC patients. The distribution of cancer stages in the final analysis was: stage I accounted for 37% of cases, stage II for 27%, stage III for 32%, and stage IV for 4%. The median preoperative PGRN level was 50.69 pg/mL, 95% CI: 47.71-56.30, n=93. When compared to preoperative levels, significantly elevated (P<0.001) median levels (pg/mL) were noted on postoperative day (POD) 1 (64.78, 95% CI: 60.86-68.83, n=92), POD 3 (69.15, 95% CI: 66.43-74.32, n=85), POD 7-13 (63.93, 95% CI: 59.62-68.35, n=68), and POD 14-20 (68.19, 95% CI: 60.12-73.37, n=26), POD 21-27 (67.38, 95% CI: 60.30-76.65, n=20) and on POD 28-41 (75.13, 95% CI: 54.02-83.16, n=22; P<0.01).
Following surgery for CRC, plasma PGRN levels showed a significant increase compared to baseline levels, persisting for a duration of one month. This initial surge post-operation could potentially be attributed to the transient acute inflammatory response. The elevation observed in weeks 2 and 4 could potentially be attributed to the process of wound healing, as PGRN has been shown to enhance the accumulation of fibroblasts and facilitate angiogenesis within wounds. Additional investigation is warranted.
颗粒蛋白前体(PGRN),也被鉴定为前体细胞衍生生长因子(PCDGF),是一种在全身广泛表达和释放的糖蛋白。PGRN在调节细胞增殖、分化和病理途径中起关键作用。PGRN在许多癌症中过表达,并在伤口愈合中起重要作用。手术对PGRN水平的影响尚不清楚。本研究的目的是评估结直肠癌(CRC)切除的微创结直肠切除(MICR)术前、术中及术后第一个月血浆PGRN水平。
研究纳入了经机构审查委员会批准的数据/血浆库且接受了MICR且有足够血浆样本的CRC患者。在手术前和术后不同时间间隔采集血样,后期样本按7天分组并视为单个时间点。通过酶联免疫吸附测定(ELISA)重复测定PGRN水平(pg/mL),并报告为中位数和95%置信区间(95%CI)值。采用配对检验进行统计分析。
93例接受MICR的CRC患者有术前及术后1次或更多次后期血浆样本。最终分析中癌症分期分布为:I期占病例的37%,II期占27%,III期占32%,IV期占4%。术前PGRN水平中位数为50.69 pg/mL,95%CI:47.71 - 56.30,n = 93。与术前水平相比,术后第1天(POD 1)(64.78,95%CI:60.86 - 68.83,n = 92)、POD 3(69.15,95%CI:66.43 - 74.32,n = 85)、POD 7 - 13(63.93,95%CI:59.62 - 68.35,n = 68)、POD 14 - 20(68.19,95%CI:60.12 - 73.37,n = 26)、POD 21 - 27(67.38,95%CI:60.30 - 76.65,n = 20)和POD 28 - 41(75.13,95%CI:54.02 - 83.16,n = 22;P < 0.01)的中位数水平(pg/mL)显著升高(P < 0.001)。
CRC手术后,血浆PGRN水平与基线水平相比显著升高,持续一个月。术后初期的这种激增可能归因于短暂的急性炎症反应。第2周和第4周观察到的升高可能归因于伤口愈合过程,因为PGRN已被证明可增强成纤维细胞的积累并促进伤口内血管生成。有必要进行进一步研究。